Main > GASTROENTEROLOGY > Colitis > Ulcerative Collitis > Treatment. > MeSalamine; MeSalazine (NSAID) > Co.: USA. Sa. (Phase III/Patents) > Phase III Results:

---

Co. today announced the successful completion and outcome of the second of two Phase III registration trials to evaluate the safety and efficacy of the Company s new granulated mesalamine product currently under development for the maintenance of remission in patients with ulcerative colitis. Results from the study indicate that a statistically significantly greater proportion of subjects dosed once–a–day with 1.5 grams of granulated mesalamine remained relapse–free over 6 months of treatment than patients dosed with placebo.
"The outcome of this second, 300–subject, multicenter, 6–month, double–blind, randomized, placebo–controlled study confirms the results of the study we reported in September 2007. The results of this second study again demonstrate the utility of our novel delayed and extended release formulation of mesalamine, dosed once a day in this study, to successfully maintain remission in ulcerative colitis patients. We continue to anticipate a December 2007 NDA submission for this product."



Phase III Results:'s products
This section has no products